Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.
Oppenheimer Downgrades PLx Pharma to Perform
Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.
Related Posts
What 8 Analyst Ratings Have To Say About Ally Financial
November 30, 9:00 AM
Analysts have provided the following ratings for Ally Financial (NYSE:ALLY) within the last quarter: Bullish Somewhat Bullish Indifferent…
Definitive Healthcare Draws Contrasting Analyst Views After CEO Resigns: One Downgrades, Another Is Optimistic
January 17, 4:18 PM
Definitive Healthcare undergoes leadership change. Interim CEO appointed; financial guidance reaffirmed for Q4 2023.
RBC Capital Maintains Outperform on Cognizant Tech Solns, Lowers Price Target to $88
July 28, 10:15 AM
RBC Capital analyst Daniel Perlin maintains Cognizant Tech Solns (NASDAQ:CTSH) with a Outperform and lowers the price target from $97 to $88.